EP4364807A2 — Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder
Assigned to Institute of Cancer Research Royal Cancer Hospital · Expires 2024-05-08 · 2y expired
What this patent protects
The present invention relates to compound represented by formula (I): or a pharmaceutically acceptable salt thereof for use in a method for the treatment or prevention of cancer, wherein the cancer is selected from the group consisting of multiple myeloma, non-small cell lu…
USPTO Abstract
The present invention relates to compound represented by formula (I): or a pharmaceutically acceptable salt thereof for use in a method for the treatment or prevention of cancer, wherein the cancer is selected from the group consisting of multiple myeloma, non-small cell lung cancer, ovarian cancer, malignant melanoma, pancreatic cancer, and colorectal cancer, the method comprising: (a) administering said compound or salt twice weekly for 3 weeks, (b) pausing administration of said compound or salt for the following 1 week, and (c) subsequently repeating steps (a) and (b) at least once.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.